Arena Pharmaceuticals, Inc. is a biopharmaceutical company located in San Diego, California. The company is developing oral medications that target G-protein-coupled receptors. Currently none of the drugs is approved by the U.S. Food and Drug Administration, but several are in Phase I to III testing, namely (stand January 2009): Lorcaserin, Phase III, indication: obesity. APD791, Phase I, indication: arterial thrombosis. APD916, entering Phase I, indication: pulmonary hypertension.

PropertyValue
dbpedia-owl:Company/industry
dbpedia-owl:Organisation/keyPersonPosition
  • Jack Lief, cofounder and CEO
    Dominic Behan, co-founder and senior scientist
dbpedia-owl:Organisation/location
dbpedia-owl:Organisation/type
dbpedia-owl:industry
dbpedia-owl:keyPersonPosition
  • Jack Lief, cofounder and CEO
    Dominic Behan, co-founder and senior scientist
dbpedia-owl:location
dbpedia-owl:type
dbpprop:abstract
  • Arena Pharmaceuticals, Inc. is a biopharmaceutical company located in San Diego, California. The company is developing oral medications that target G-protein-coupled receptors. Currently none of the drugs is approved by the U.S. Food and Drug Administration, but several are in Phase I to III testing, namely (stand January 2009): Lorcaserin, Phase III, indication: obesity. APD791, Phase I, indication: arterial thrombosis. APD916, entering Phase I, indication: pulmonary hypertension. Niacin receptor antagonist, Phase I, indication: arteriosclerosis, (in conjunction with Merck) ADP597, Phase II, indication: diabetes type 2, (in conjunction with Ortho-McNeil-Janssen)
dbpprop:companyName
  • Arena Pharmaceuticals
dbpprop:companyType
dbpprop:homepage
dbpprop:industry
dbpprop:keyPeople
  • Jack Lief, cofounder and CEO Dominic Behan, co-founder and senior scientist
dbpprop:location
dbpprop:products
  • in development
dbpprop:reference
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • Arena Pharmaceuticals, Inc. is a biopharmaceutical company located in San Diego, California. The company is developing oral medications that target G-protein-coupled receptors. Currently none of the drugs is approved by the U.S. Food and Drug Administration, but several are in Phase I to III testing, namely (stand January 2009): Lorcaserin, Phase III, indication: obesity. APD791, Phase I, indication: arterial thrombosis. APD916, entering Phase I, indication: pulmonary hypertension.
rdfs:label
  • Arena Pharmaceuticals
skos:subject
foaf:homepage
foaf:name
  • Arena Pharmaceuticals
foaf:page